Isofol’s rights issue fully subscribed – exercises overallotment for Japanese partner
GOTHENBURG, Sweden, 4 July 2025 – Isofol Medical AB (“Isofol” or the “Company”) today announces the outcome of the Company’s […]
Issuance
Isofol announces final terms of the rights issue and the potential overallotment issue
GOTHENBURG, Sweden, 5 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or
The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million
GOTHENBURG, Sweden, 12 May 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or
Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option
GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the
Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 18, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million
GOTHENBURG, Sweden, April 28, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that
Isofol’s rights issue oversubscribed
GOTHENBURG, Sweden, June 3, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the
Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million
GOTHENBURG, Sweden, May 7, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million
GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that
Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today
Isofol Medical AB (publ), a clinical stage pharmaceutical company, hereby announces that the offering of newly issued shares in the